A Selected Reaction Monitoring Mass Spectrometric Assessment Of Biomarker Candidates Diagnosing Large-Cell Neuroendocrine Lung Carcinoma By The Scaling Method Using Endogenous References

Selected reaction monitoring mass spectrometry (SRM-MS) -based semi-quantitation was performed to assess the validity of 46 selected candidate proteins for specifically diagnosing large-cell neuroendocrine lung carcinoma (LCNEC) and differentiating it from other lung cancer subtypes. The scaling method was applied in this study using specific SRM peak areas (AUCs) derived from the endogenous reference protein that normalizes all SRM AUCs obtained for the candidate proteins. In a screening verification study, we found that seven out of the 46 candidate proteins were statistically significant for the LCNEC phenotype, including 4F2hc cell surface antigen heavy chain (4F2hc/CD98) (p-ANOVA <= 0.0012), retinal dehydrogenase 1 (p-ANOVA <= 0.0029), apolipoprotein A-I (p-ANOVA <= 0.0004), beta-enolase (p-ANOVA <= 0.0043), creatine kinase B-type (p-ANOVA <= 0.0070), and galectin3- binding protein (p-ANOVA = 0.0080), and phosphatidylethanolamine-binding protein 1 (p-ANOVA <= 0.0012). In addition, we also identified candidate proteins specific to the small-cell lung carcinoma (SCLC) subtype. These candidates include brain acid soluble protein 1 (p-ANOVA < 0.0001) and.-enolase (p-ANOVA <= 0.0013). This new relative quantitation-based approach utilizing the scaling method can be applied to assess hundreds of protein candidates obtained from discovery proteomic studies as a first step of the verification phase in biomarker development processes.